Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine

Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine

Abstract Background The four co-circulating and immunologically interactive dengue virus serotypes (DENV1-4) pose a unique challenge to vaccine design because sub-protective immunity can increase the risk of severe dengue disease. Existing dengue vaccines have lower efficacy in DENV seronegative ind...

Full description

Bibliographic Details
Main Authors: Camila D. Odio, Kelsey E. Lowman, Melissa Law, Rosemary A. Aogo, Sally Hunsberger, Brad J. Wood, Michael Kassin, Elliot Levy, Viviane Callier, Saba Firdous, Chloe M. Hasund, Charlie Voirin, Robbie Kattappuram, Christina Yek, Jessica Manning, Anna Durbin, Stephen S. Whitehead, Leah C. Katzelnick
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Infectious Diseases
Subjects:
Dengue
Vaccine
Live-attenuated
Primary
Secondary
Tertiary
Online Access:https://doi.org/10.1186/s12879-023-08299-5

Internet

https://doi.org/10.1186/s12879-023-08299-5

Similar Items